Physician profile
Ashley Walker
NPI 1033629738
$9,367.74
in general payments reported to CMS, 2019-2025
35 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.56 · 2020: $586 · 2021: $1,580 · 2022: $1,622 · 2023: $1,802 · 2024: $2,475 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,542.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,833.38 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,672.09 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $757.25 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $713.30 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $639.73 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $345.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.10 | 2020-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.32 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $295.62 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $253.08 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $249.54 | 2021-2024 | Trintellix |
| Amgen INC. | $213.39 | 2023-2025 | Otezla, Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company Ltd. | $186.99 | 2022 | |
| Dexcom, INC. | $173.48 | 2023-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $164.97 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $147.37 | 2020-2023 | Belsomra |
| Currax Pharmaceuticals LLC | $128.52 | 2021-2025 | Contrave, Onzetra Xsail |
| Vivus LLC | $124.97 | 2023 | Qsymia |
| Abbott Laboratories | $120.88 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Intuitive Surgical, INC. | $93.13 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $79.74 | 2020-2025 | Livalo, Zoryve |
| Paratek Pharmaceuticals, INC. | $75.80 | 2024-2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $66.77 | 2021 | |
| Shield Therapeutics INC | $59.11 | 2023-2025 | Accrufer |
| Kvk-Tech, INC. | $54.55 | 2025 | |
| Allergan, INC. | $42.86 | 2020 | |
| Viiv Healthcare Company | $41.89 | 2022 | |
| Boston Scientific Corporation | $36.65 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $34.98 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $31.43 | 2025 | Symbravo |
| Janssen Pharmaceuticals, INC | $24.21 | 2019 | |
| Biogen, INC. | $19.08 | 2021 | |
| Medline Industries Lp | $18.59 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.00 | 2023 | Quviviq |
| Corcept Therapeutics | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.